Targeted alpha therapy: part I.

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Chemistry

Background:

• The concept of targeted cancer therapy, aiming for precision eradication of tumors and single cancer cells, has evolved significantly since its inception.
• Targeted Alpha Therapy (TAT) leverages highly specific targeting constructs linked to alpha-particle emitting radionuclides for potent cancer cell destruction.
• The short range of alpha particles offers a therapeutic advantage by minimizing off-target irradiation of surrounding healthy tissues.

Discussion:

• Recent advancements in identifying novel biological targets, developing sophisticated targeting constructs, and refining radiolabeling techniques are accelerating TAT research.
• Challenges such as limited diffusion of radioimmunocomplexes and inhomogeneous activity distribution within tumors require further investigation and innovative solutions.
• The availability of alpha-particle emitting radionuclides, like 211At, is critical and necessitates investment in cyclotron infrastructure and beam-time prioritization.

Key Insights:

• The development of stable radioimmunocomplexes with high specific activity is essential for effective TAT delivery.
• Understanding and optimizing the chemical and radiochemical aspects of labeling are crucial for creating effective alpha-particle emitting radiopharmaceuticals.
• Pre-targeting strategies show promise in improving activity distribution and enhancing the tumor-to-normal tissue absorbed dose ratio.

Outlook:

• Continued research into radionuclide availability, biomolecular targeting, labeling chemistry, and dosimetry is vital for advancing TAT.
• The establishment of controlled, randomized clinical trials with adequate patient numbers is imperative for validating TAT efficacy and comparing different approaches.
• Overcoming current challenges will pave the way for TAT to become a standard treatment modality, particularly for micrometastatic cancers.